Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ingrid A MayerKathy D Miller

Abstract

Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence, which is reduced by adjuvant capecitabine. Preclinical models support the use of platinum agents in the TNBC basal subtype. The EA1131 trial hypothesized that invasive disease-free survival (iDFS) would not be inferior but improved in patients with basal subtype TNBC treated with adjuvant platinum compared with capecitabine. Patients with clinical stage II or III TNBC with ≥ 1 cm RD in the breast post-NAC were randomly assigned to receive platinum (carboplatin or cisplatin) once every 3 weeks for four cycles or capecitabine 14 out of 21 days every 3 weeks for six cycles. TNBC subtype (basal v nonbasal) was determined by PAM50 in the residual disease. A noninferiority design with superiority alternative was chosen, assuming a 4-year iDFS of 67% with capecitabine. Four hundred ten of planned 775 participants were randomly assigned to platinum or capecitabine between 2015 and 2021. After median follow-up of 20 months and 120 iDFS events (61% of full information) in the 308 (78%) patients with basal subtype TNBC, the 3-year iDFS for platinum was 42% (95% CI, 30 to ...Continue Reading

References

May 4, 2005·Breast Cancer Research and Treatment·Evan MatrosAndrea L Richardson
Aug 27, 2005·Cell Cycle·Rachel ZangenDavid Sidransky
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Lisa A CareyRobert C Millikan
Apr 21, 2007·The Journal of Clinical Investigation·Chee-Onn LeongLeif W Ellisen
Jun 21, 2007·Breast Cancer Research and Treatment·Robert C MillikanCharles M Perou
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Nov 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boris FreidlinRobert Gray
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Feb 14, 2008·Clinical Breast Cancer·David RossiGiuseppina Catalano
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel G HallerChris Twelves
May 15, 2009·The New England Journal of Medicine·Hyman B MussUNKNOWN CALGB Investigators
Mar 20, 2010·Clinical Breast Cancer·Michael Naughton
Aug 28, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M KaufmannUNKNOWN GBG-39 Trialists
Aug 31, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Monika GraeserNicholas C Turner
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Jan 29, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debora de Melo GagliatoMariana Chavez-Macgregor
Apr 7, 2015·Breast Cancer Research and Treatment·Willemijne A M E SchrijverCathy B Moelans
Jan 31, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansGabriel N Hortobagyi
Jun 1, 2017·The New England Journal of Medicine·Norikazu MasudaMasakazu Toi
Dec 6, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ana LluchUNKNOWN LACOG (Latin American Cooperative Oncology Group)
Aug 18, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E L MayerE P Winer

❮ Previous
Next ❯

Citations

Sep 24, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ingrid A MayerKathy D Miller
Sep 24, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yumiko ShimanukiChikako Shimizu
Sep 24, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tatsunori ShimoiKan Yonemori

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Karama AslehSaranya Chumsri
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ana LluchLACOG (Latin American Cooperative Oncology Group)
© 2021 Meta ULC. All rights reserved